semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer HER-2 Positive Breast Cancer Triple Negative Breast Cancer ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment Pathologically confirmed diagnosis of invasive breast cancer Stage IV disease Documented HER2 and hormonal receptor status per protocol, ER/PR+ patients must be refractory to at least one prior hormonal treatment ECOG Performance status 0-1 Measurable disease per (1.1) Adequate hematological function per protocol Adequate hepatic function per protocol Adequate renal function per protocol Negative serum pregnancy test at study entry for patients of childbearing potential Ability to understand and sign written consent and to comply with the study protocol  Presence of active or untreated CNS metastases as determined by MRI/CT scan performed during screening Active malignancies other than MBC within the last 5 years except adequately treated in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin Bone as the only site of metastatic disease from breast cancer Prior radiotherapy to the only area of measurable disease. NOTE: Radiotherapy to a limited area other than the sole site of measurable disease is allowed, if received prior to initiation of ganetespib treatment. Patients must have completed treatment and recovered from all acute treatment-related toxicities prior to administration of first dose of ganetespib Pregnancy or lactation Known serious cardiac illness Uncontrolled intercurrent illness per protocol Other severe acute or chronic medical condition or abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or that in the judgment of the investigator would make the patient inappropriate for entry into the study
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 41.0-90.0,  Invasive Ductal and Invasive Lobular Breast Carcinoma Stage 0 Breast Carcinoma Stage I Breast Carcinoma Stage II Breast Carcinoma Histological proven invasive breast carcinoma ductal, lobular and/or Ductal Carcinoma in situ Age > 40 years Karnofsky performance status > 70% Tumor. Single discrete tumor or focal microcalcifications that can be imaged on a specimen radiograph or multifocal disease within the same quadrant with a maximum dimension of equal to or less than 2.5 cm Nodal Status: preoperatively N0 Clear surgical margins: R0 All grades G1 Any hormonal receptor and HER-2 status Informed consent  Gender: male Tumor size: more than 2.5 cm Nodal status greater than or equal to N1 pathologically Multicentricity Previous radiotherapy to the involved breast Karnofsky Index < 70% Mixed connective tissue diseases e.g. rheumatoid poly arthritis, thromboangitis obliterans, systemic lupus Distant metastases Pregnancy in woman of child bearing age Unable to provide written consent
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Female Patients with metastatic breast cancer, who are at least 18 years old (no upper age limit)  Contraindication according to the summary of product characteristics of Abraxane® No signed patient informed consent form available pregnant or breastfeeding patients
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 19.0-80.0,  Metastatic Melanoma Ability to understand and the willingness to sign a written informed consent document Histologic diagnosis of locally unresectable, metastatic melanoma Any BRAF status is permitted Any prior therapy is permitted except prior therapy with ipilimumab Patients must have at least 2 distinct measurable metastatic sites, with one of at least 1 cm or larger in its largest diameter and may have additional non-measurable but established metastatic lesions (i.e. bone metastases) Patients must have adequate organ and marrow function as defined by initial laboratory tests WBC 2000/uL ANC 1000/uL Platelets 50 x 103/uL Hemoglobin 8 g/dL  Patients having no lesions outside the field of radiation thus nullifying the ability to measure an abscopal effect Autoimmune disease: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab) Concomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids Women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after cessation of study drug, or have a positive pregnancy test at baseline, or are pregnant or breastfeeding Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 8 weeks after study drug is stopped Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Ductal Breast Carcinoma In Situ Estrogen Receptor Negative Estrogen Receptor Positive HER2/Neu Negative Invasive Cribriform Breast Carcinoma Invasive Ductal Carcinoma, Not Otherwise Specified Lobular Breast Carcinoma In Situ Mucinous Breast Carcinoma Papillary Breast Carcinoma Progesterone Receptor Positive Stage I Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIC Breast Cancer Tubular Breast Carcinoma Core needle biopsy (e.g. Mammotome, core, stereotactic, ultrasound guided) showing invasive mammary cancer (with or without concomitant ductal carcinoma or lobular carcinoma in situ) or ductal carcinoma in situ; acceptable histologic types of invasive mammary cancer ductal, tubular, mucinous, papillary, cribriform and "NOS" (not otherwise specified); invasive lobular cancer is excluded Age >= 50 years and postmenopausal with no menses for at least one year prior to study enrollment Age > 70 years with invasive breast cancer clinical size =< 3 cm OR Age 50 years with invasive breast cancer clinical size =< 1.5 cm OR Age >= 50 years and postmenopausal with any grade ductal carcinoma in situ (DCIS) clinical extent =< 1.5 cm (clinical tumor size will be determined by pre-operative breast imaging-mammography, ultrasound and/or magnetic resonance imaging; in cases of multiple measurements, the largest recorded single dimension will be used to determine eligibility) Hormone receptor status Estrogen or progesterone receptor positive or Estrogen and progesterone receptor negative and clinical tumor size =< 1.0 cm Human epidermal growth factor receptor 2 (HER2)/neu negative on the core biopsy analysis defined as 0 or 1+ by immunohistochemistry or not amplified by fluorescent in situ hybridization analysis Tumor >= 0.5 cm from skin as defined by breast ultrasound Unicentric tumor  Initial core biopsy showing invasive lobular cancer Estrogen receptor and progesterone receptor negative tumor with clinical size > 1 cm Any Her 2+ breast cancer (immunohistochemistry 3+; or amplified by fluorescence in situ hybridization [FISH]) Cancer in a patient with a known inherited susceptibility mutation in breast cancer (BRCA)1 or BRCA2 Multicentric breast cancer (two foci of known cancer in the breast separated by greater than 5 cm, or in separate quadrants Clinically or pathologically positive axillary lymph nodes Any prior breast cancer Prior breast radiation therapy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  ST Elevation Myocardial Infarction, Multivessel Coronary Artery Disease Subject must be at least 18 years of age Subject is able to verbally confirm understandings of risks, benefits of treatment of either multivessel stenting or staged PCI using the zotarolimus-eluting stent (Resolute Integrity™ Stent, Medtronic) and he or she or his or her legally authorized representative provides written informed consent prior to any study related procedure Subject must have significant stenoses (≥ 70%) of two or more than two of coronary arteries and requiring primary PCI for acute ST elevation myocardial infarction (STEMI) within 12hrs Target lesion(s) must be located in a native coronary artery with visually estimated diameter of less than 2.5 mm and more than 4.0 mm Target lesion(s) must be amenable for percutaneous coronary intervention  The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin Aspirin Both Clopidogrel and Ticlopidine, Zotarolimus Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 6 months post enrollment Non-cardiac comorbid conditions are present with life expectancy over 1 year or that may result in protocol non-compliance (per site investigator's medical judgment) Acute heart failure Killip III-IV ≥ 50% left main stenosis
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms, Breast Female patients aged 18 years or older at diagnosis of, or progression to, metastatic breast cancer Patients with a diagnosis of breast cancer with documented metastatic disease and with known date of metastatic disease Patients with a histologically confirmed HER2+ breast cancer (HER2 testing procedures per routine institutional practice; no tissue re-sampling will be performed. If conducted at another site, documented results must be available)  Patients receiving care for another primary cancer during the study time period
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Carcinoma Breast Stage I HER2 Positive Breast Cancer Criteria:a. 1. Female subjects aged 18 years or older. 2. Histologically and/or cytologically confirmed diagnosis of breast cancer. Clinical stages breast cancer: HER2 positive, T1 or T2 or T3, N0 or N1, resectable T4, or resectable N2, (all M0) 3. Documentation of erbB-2 gene amplification by FISH (as defined by a ratio >2.2) or chromogenic in situ hybridization (CISH, as defined by the manufacturer's kit instruction) or documentation of erbB-2-overexpression by IHC (defined as IHC3+, or IHC2+ with FISH or CISH confirmation) based on local laboratory. 4. LVEF within institutional range of normal as measured by MUGA or ECHO. 5. Screening laboratory values within the following parameters: 1. Absolute neutrophil count (ANC) ≥1.5 x 109 /L (1500/mm3) 2. Platelet count ≥100 x 109/L (100,000/mm3) 3. Hemoglobin ≥9.0 g/dL (90 g/L) 4. Serum creatinine ≤1.5 x upper limit of normal (ULN) 5. Total bilirubin ≤1.5 x ULN (<3 ULN if Gilbert's disease) 6Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 5 x ULN  Bilateral breast cancer 2. Active uncontrolled cardiac disease, including cardiomyopathy, CHF (New York Heart Association [NYHA] functional classification of ≥3), unstable angina, and myocardial infarction (within 12 months of study entry). 3. Inadequately controlled hypertension (ie, systolic blood pressure [BP] > 180 mm Hg or diastolic BP > 100 mm Hg). 4. Family history of congenital long or short QT syndrome, Brugada syndrome or QT/QTc interval > 0.45 second or known history of QT/QTc prolongation or torsade de pointe (TdP). 5. Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn's disease, malabsorption, or grade ≥2 diarrhea of any etiology at baseline). 6. Women who are pregnant, breast-feeding
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Ductal Breast Carcinoma in Situ Invasive Ductal Breast Carcinoma Stage IA Breast Cancer Stage IB Breast Cancer Postmenopausal state Histological diagnosis of breast invasive ductal carcinoma with receptor profiles obtained MRI visible breast lesion Unifocal cancer, less than 1.5 cm in maximum diameter (clinical stage T1), with no evidence of extensive in situ cancer surrounding the main tumor; the will be determined by the MR imaging appearance of the tumor; if the tumor (proven invasive ductal carcinoma) is a unifocal mass without additional enhancement, it will be judged eligible; however, if the tumor is associated with additional enhancement and/or a satellite focus, it will not judged ineligible, as these are signs of additional in situ or invasive cancer Clinical stage N0 (no metastatic axillary lymph node on physical examination or imaging work-up) Ability to give informed consent  Previous surgery or radiation for the ipsilateral breast cancer Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI Tumor located less than 1 cm from the skin or the pectoralis muscle
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltration IV Infiltration years or older signed consent health form approved by professional practitioner  abnormal bleeding or hemophilia absence of sensation in arms anemia cardiopulmonary disorders clotting disorders dehydration dizziness or fainting hepatitis high blood pressure (>160 systolic or > 115 diastolic) HIV / AIDS
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Breast Cancer female patients with metastatic breast cancer seeing one of the study physicians at one of the identified study clinics age 21 or older having suspected progression of metastatic disease  patients with an uncorrectable hearing impairment or having limited English proficiency, as this would adversely affect their ability to communicate with the physician patients with uncorrectable vision impairment, as this would make it impractical for the patient to read the intervention patients too ill to meaningfully converse with the physician
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II Patients must be greater than or equal to 18 years of age Patients must have a newly diagnosed invasive ductal breast carcinoma, Stage I-II Patients who have completed their surgical and radiation therapy Patients must have SWOG performance status of 0, 1 or 2 Patients must have adequate organ function as defined by Hgb > 8.0 gm/dl, WBC > 3,500, platelet count > 100,000 Bilirubin < 2.0 mg/dl, SGOT < 4x upper limit of normal Creatinine < 2.0 mg/dl or calculated creatinine clearance > 50 ml/min Patients must have a serum calcium phosphate product that is less than 70  Patients with histology of lobular carcinoma Patients with metastatic disease Pregnant or lactating women Male gender Patients with a history of sarcoidosis Patients with any history of idiopathic urinary calcium stone disease, chronic hypercalcemia, or gastrointestinal malabsorptive conditions Patients who have received any of the following treatments within the last 14 days prior to study registration will be excluded Lithium Digitalis Thiazide diuretics